AVIR (Atea Pharmaceuticals) YoY EPS Growth: 6.82% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AVIR Atea Pharmaceuticals Inc AVIR
28 GF Score
Price $5.34
! 3 Warning Signs
View Full Analysis

What is Atea Pharmaceuticals YoY EPS Growth?

Atea Pharmaceuticals AVIR -0.37% 28 YoY EPS Growth is 6.82% as of Jun. 2026. GuruFocus rates AVIR with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Atea Pharmaceuticals's YoY EPS Growth for the quarter that ended in Jun. 2026 was 6.82%.

Atea Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was $-0.41.

Atea Pharmaceuticals YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Atea Pharmaceuticals's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atea Pharmaceuticals YoY EPS Growth Chart

Atea Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EPS Growth
Get a 7-Day Free Trial 368.63 -201.46 -17.27 -22.70 3.00

Atea Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.33 -43.24 -42.50 -42.50 6.82
AVIR
28GF Score
Atea Pharmaceuticals Inc AVIR
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atea Pharmaceuticals YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Atea Pharmaceuticals's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(-1.94--2)/ | -2 |
=3.00 %

Atea Pharmaceuticals's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(-0.41--0.44)/ | -0.44 |
=6.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 6.82% mean?
Atea Pharmaceuticals (AVIR) has a YoY EPS Growth of 6.82% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Atea Pharmaceuticals and its competitors.
Is Atea Pharmaceuticals' YoY EPS Growth too high?
Atea Pharmaceuticals' current YoY EPS Growth is 6.82%. Overall, Atea Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Atea Pharmaceuticals' YoY EPS Growth compare to BNTC and ARCT?
Atea Pharmaceuticals' YoY EPS Growth of 6.82% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Atea Pharmaceuticals and its competitors. Atea Pharmaceuticals's current YoY EPS Growth is 6.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atea Pharmaceuticals stock overvalued right now?
Atea Pharmaceuticals (AVIR) has a current YoY EPS Growth of 6.82%. The current YoY EPS Growth is 6.82%. Atea Pharmaceuticals' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Atea Pharmaceuticals (AVIR), the current YoY EPS Growth is 6.82% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atea Pharmaceuticals Business Description

Address 225 Franklin Street, Suite 2100, Boston, MA, USA, 02110
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
28GF Score

Get the complete analysis for AVIR

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.34
Price